(Q40558841)

21 September 2017

title

Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: a randomised phase II-study (English)

1 reference

21 September 2017

6

Hans E Johnsen

1 reference

21 September 2017

Bo Björkstrand

1

1 reference

21 September 2017

Thomas Rasmussen

2

1 reference

21 September 2017

Kari Remes

3

1 reference

21 September 2017

Astrid Gruber

4

1 reference

21 September 2017

Tarja-Terttu Pelliniemi

5

1 reference

21 September 2017

publication date

1 June 2003

1 reference

European Journal of Haematology

21 September 2017

published in

1 reference

21 September 2017

volume

70

1 reference

21 September 2017

issue

6

1 reference

21 September 2017

page(s)

379-383

1 reference

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00068.X

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00068.X

7 January 2021

Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00068.X

7 January 2021

Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00068.X

7 January 2021

Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00068.X

7 January 2021

Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00068.X

7 January 2021

Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00068.X

7 January 2021

Nucleoside analogues: mechanisms of drug resistance and reversal strategies.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00068.X

7 January 2021

Circulating clonal cells in multiple myeloma do not express CD34 mRNA, as measured by single-cell and real-time RT-PCR assays

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00068.X

7 January 2021

Efficacy and safety of CD34-selected and CD19-depleted autografting in multiple myeloma patients: a pilot study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00068.X

7 January 2021

The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00068.X

7 January 2021

10.1034/J.1600-0609.2003.00068.X

Identifiers

DOI

1 reference

21 September 2017

1 reference